Ophthalmic Therapeutic Drugs: Technologies and Global Markets

Ophthalmic Therapeutic Drugs: Technologies and Global Markets

Report Code: PHM031D

Publish Date: Jul 2015

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global ophthalmic therapeutic drug market was valued at $12.3 billion in 2014. This market is expected to reach $19 billion by 2019, with a compound annual growth rate (CAGR) of 9.1% from 2014 to 2019.

Report Includes

  • An overview of the global market for ophthalmic therapeutic drugs.
  • Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
  • Investigation of one of the most important market drivers, combination therapies.
  • Learn how healthcare awareness and emerging middle classes in countries such as India, China, Brazil and Russia are providing market opportunities.
  • Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.
  • Analysis of these major players to help define the specific product strategies which they are employing.

SCOPE OF REPORT

This report on ophthalmic therapeutics drugs provides a brief description of the current status of the industry and recent developments. The report analyzes the market trends, and identifies key therapeutic and geographical challenges and rising opportunities in the developed and developing world. Finally, it will provide insights into new developments into ophthalmic therapeutics including novel biologics, formulations and the launch of biosimilars and generics.

ANALYST’S CREDENTIALS

Dr. C. L. Barton has more than 10 years of practical pharmaceutical research experience with a leading pharmaceutical company, and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C. L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.

Need pricing for multiple titles, a complete report bundle, or something specially curated to fit your budget? Explore Offers
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Ophthalmic Therapeutic Drugs: Technologies and Global Markets111Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY 3Free
Chapter- 3: RETINAL DISEASES: AGE-RELATED MACULAR DEGENERATION19Free
Chapter- 4: GLAUCOMA27Free
Chapter- 5: DRY EYE SYNDROME14Free
Chapter- 6: UVEITIS13Free
Chapter- 7: RECENT MARKET ACTIVITY13Free
Chapter- 8: C. CRAMER & CO. GMBH11Free
Chapter- 9: APPENDIX I: ACRONYMS1Free
Chapter- 10: APPENDIX II: REFERENCES7Free

Related Reports

Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging

Published - Jun 2015 | Publisher - Shalini Shahani Dewan | Code - PHM043F

The global market for contract pharmaceutical manufacturing, research and packaging totaled $248.5 billion in 2014 and is projected to approach $352.8 billion by 2019, registering a compound annual growth rate (CAGR) of 7.3% through 2019.

Global Markets for Drug-Device Combinations

Published - Jan 2015 | Publisher - Kevin Gainer | Code - PHM045D

The sales of drug-device combination products reached $21.4 billion in 2013 and $22 billion in 2014. This market is expected to grow to $31 billion in 2019, with a compound annual growth rate (CAGR) of 7.1% from 2014 to 2019.

Global Markets for Generic Drugs

Published - Jan 2014 | Publisher - Paul Evers | Code - PHM009G

The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

Global Markets and Technologies for Advanced Drug Delivery Systems

Published - Jan 2014 | Publisher - Shalini Shahani Dewan | Code - PHM006J

The global revenue for advanced drug delivery systems is estimated to be $151.3 billion in 2013. In 2018,  revenues are estimated to reach nearly $173.8 billion, demonstrating a compound annual growth rate (CAGR) of 2.8%.

Track the Latest Global Tariff Developments

In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.

Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.

Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.

With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.

Ready to see what tariff means for your business?

Consult with our experts or request your custom Tariff Impact Brife today

Stay Informed, Stay Competitive

In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.

Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.

Our analysis includes:

  • Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
  • Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
  • Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.

With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.

Don't let tariffs catch you off guard—let our insights guide your strategy.

This is an Excel-only version of the report.

Report Includes

    Total Number of Tables in this Report: 53

  • Summary Table: GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT, THROUGH 2019
  • Table 1: PRODUCTS APPROVED TO TREAT WET AMD
  • Table 2: GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019
  • Table 3: GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019
  • Table 4: GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019
  • Table 5: AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT
  • Table 6: PRODUCTS IN DEVELOPMENT FOR WET AMD – PHASE III
  • Table 7: PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II
  • Table 8: PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I
  • Table 9: PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III
  • Table 10: PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II
Sample Report

Recent Reports

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

Published - Jul 2025 | Publisher - BCC Publishing | Code - PHM072B

The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.

Anti-Parkinson's Drugs: Global Markets to 2030

Published - Jul 2025 | Publisher - BCC Publishing | Code - PHM193B

The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.

Global Markets for Infectious Disease Treatments

Published - Jul 2025 | Publisher - BCC Publishing | Code - PHM061F

The global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 and is projected to reach $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.

Disease-Modifying Therapies for Alzheimer’s Disease: Global Markets

Published - Jun 2025 | Publisher - BCC Publishing | Code - PHM283A

This report provides an overview of the global and regional markets for disease-modifying therapies for Alzheimer’s disease. It includes global revenue ($ million) for base year data of 2024, estimates for 2025, and CAGR forecasts through 2030.

Global Markets for Allergy Diagnostics and Treatments

Published - Jun 2025 | Publisher - BCC Publishing | Code - PHM026D

The global market for allergy diagnostics and treatment is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030, at a compound annual rate growth (CAGR) of 7.3% from 2025 through 2030.

Published - Apr-2010| Analyst - Jackson Highsmith| Code - PHM031C

Report Highlights

  • The global ophthalmic therapeutic market was valued at $15.5 billion in 2009, showing a growth rate of more than 2½ times that of the overall pharmaceutical industry.  The sector will continue to grow through 2014 to $20.6 billion,  a compound annual growth rate (CAGR) of 5.9%.
  • As a segment, glaucoma recorded $5.8 billion in 2009 revenue. Six leading glaucoma products will come off patent before 2012, resulting in a compound annual growth rate (CAGR) of 3.6% and estimated revenues of $6.6 billion in 2014. 
  • Treatment for wet AMD recorded sales of $2.4 billion in 2009. This sector is projected to grow at a 10% compound annual growth rate (CAGR) through 2014 to reach $3.9 billion.
Published - Sep-2006| Analyst - Melissa Elder| Code - PHM031B

Report Highlights

  • The U.S. ophthalmic market is worth $9.6 billion in 2006, up from $8.8 billion in 2005. At an average annual growth rate (AAGR) of 7.4%, the market will cross $13.8 billion in 2011.
  • Ophthalmic pharmaceuticals dominated the market throughout the forecast period. In 2006 pharmaceuticals comprised 46.6% of the market and, growing at an AAGR of 6.9%, will be worth more than $6.2 billion and maintain more than 45% of the market in 2011.
  • Contact lenses include both functional and cosmetic lenses. Contact lenses generate approximately $1.9 billion in revenues annually in the United States, accounting for a near 20% of the market.
Published - Aug-2003| Analyst - Melissa Elder| Code - PHM031A

Report Highlights

  • The 2002 U.S. market for prescription ophthalmic drugs was $2.8 billion, and, rising at an average annual growth rate (AAGR) of 8.6%, will reach $4.5 billion in 2007.
  • Glaucoma treatments accounted for $1.4 billion in 2002 and will grow at an AAGR of 8.2% to more than $2 billion in 2007.
  • Products within the ocular infection and ocular allergy treatment segments follow in market presence, with $500 million and $397.1 million, respectively.
  • Ocular allergy treatment will lead growth with an AAGR of 10% through the period, reaching nearly $640 million

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Ophthalmic Therapeutic Drugs: Technologies and Global Markets
Customize Report